What to Know About the Approval of Lecanemab-irmb

In an interview with Pharmacy Times, Nikhil Palekar, MD, director of the Stony Brook Center of Excellence for Alzheimer Disease, director of the Stony Brook Division for Geriatric Psychiatry, and director of the Stony Brook Alzheimer Disease clinical trials program, discussed the FDA approval of lecanemab-irmb (Leqembi, Eisai) and what this means for those who have Alzheimer Disease.

Although the treatment is not a cure and cannot reverse early Alzheimer disease, Palekar said it could give patients crucial more time to join other clinical trials investigating potential treatments.